{name}
{subtitle}
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~79 mi. (Oviedo, Spain, +93 more cities)
facility
Hospital Universitario Central de Asturias ( Site 0654)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
city
~79 mi. (Oviedo, Spain, +199 more cities)
facility
Hospital Central de Asturias ( Site 0667)
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
city
~79 mi. (Oviedo, Spain, +45 more cities)
facility
Hospital Universitario General de Asturias ( Site 1601)
drug
cisplatin, +5 more drugs
drug type
chemotherapy, +2 more types
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~79 mi. (Oviedo, Spain, +122 more cities)
facility
Hospital Universitario Central de Asturias ( Site 1900)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
city
~79 mi. (Oviedo, Spain, +179 more cities)
facility
Hospital Universitario Central de Asturias
drug
atezolizumab, +1 more drug